Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
Conditions
Interventions
Selonsertib
Locations
5
United States
Denver, Colorado, United States
Miami, Florida, United States
Orlando, Florida, United States
Minneapolis, Minnesota, United States
San Antonio, Texas, United States
Start Date
August 18, 2015
Primary Completion Date
December 15, 2015
Completion Date
December 15, 2015
Last Updated
January 27, 2021
NCT07271186
NCT06600412
NCT05822609
NCT06846034
NCT06291155
NCT06441591
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions